DEF: NextCure Seeks Stockholder Approval for Reverse Stock Split to Maintain Nasdaq Listing

NextCure is asking stockholders to approve a reverse stock split to maintain its Nasdaq listing and is holding advisory votes on executive compensation at its 2025 annual meeting.

Summary

• NextCure is holding its 2025 Annual Meeting of Stockholders virtually on June 20, 2025.
• Stockholders will vote on several proposals, including the election of three Class III directors, ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm, and advisory votes on executive compensation.
• A key proposal is an amendment to the company's certificate of incorporation to effect a reverse stock split at a ratio between 1:5 and 1:15, if and when determined by the Board of Directors.
• The company received a Nasdaq notice on January 31, 2025, stating that its stock price had fallen below the minimum average closing price of $1.00 per share, requiring a reverse stock split to regain compliance.
• The Board is also seeking approval to adjourn the Annual Meeting to solicit additional proxies if necessary to pass the reverse stock split proposal.
• For the first time in 2025, NextCure will be holding advisory votes relating to officer compensation, including a Say-on-Pay vote and a Say-on-Frequency vote.

Sentiment

Score: 6

Explanation: The document is neutral in tone, primarily focusing on procedural matters related to the annual meeting and the reverse stock split. The need for a reverse stock split is a negative signal, but the company is taking steps to address the issue.

Positives

• The Board is taking proactive steps to address the Nasdaq minimum bid price requirement through the proposed reverse stock split.
• The company is engaging with stockholders on executive compensation through advisory votes.
• The virtual meeting format is expected to encourage higher levels of stockholder participation while reducing costs.
• The company has a robust corporate governance framework with independent directors and active committees.

Negatives

• The need for a reverse stock split indicates that the company's stock price has been underperforming.
• Reverse stock splits can have a negative perception and may not always lead to a sustained increase in stock price.
• There is no guarantee that the reverse stock split will enable the company to maintain its Nasdaq listing.
• The company is not aware of any present efforts by anyone to accumulate our common stock, and the proposed reverse stock split is not intended to be an anti-takeover device.

Risks

• The reverse stock split may not increase the market price of the common stock.
• The company may not meet the requirements for continued listing on the Nasdaq stock market even after the reverse stock split.
• The market price of the common stock could decline after the reverse stock split.
• The issuance of additional shares after the reverse stock split could be dilutive to existing stockholders.
• The company is exposed to risks and uncertainties described in its most recent Annual Report on Form 10-K.

Future Outlook

The company is focused on discovering and developing innovative medicines for cancer patients and is advancing its LNCB74 program in a Phase 1 trial.

Management Comments

• The Board of Directors is committed to governance practices that are appropriately tailored to our business and guiding NextCure toward delivering on our commitment to discovering and developing innovative medicines.
• We look forward to your participation at the Annual Meeting.

Industry Context

The company operates in the competitive biopharmaceutical industry, focused on developing immunotherapies for cancer and other diseases.

Comparison to Industry Standards

• The peer group for executive compensation includes Actinium Pharmaceuticals, Inc., Carisma Therapeutics, Inc., and other similar-sized biopharmaceutical companies.
• The company's executive compensation practices are benchmarked against this peer group to ensure competitiveness.

Stakeholder Impact

• The reverse stock split could impact stockholders by changing the number of shares they own and potentially affecting the stock price.
• The company's ability to maintain its Nasdaq listing is important for investor confidence and access to capital.
• Executive compensation decisions impact the alignment of management's interests with those of stockholders.

Next Steps

• Stockholders will vote on the proposals at the Annual Meeting on June 20, 2025.
• The Board will determine whether to implement the reverse stock split based on market conditions and other factors.
• The company will continue to advance its clinical programs and seek potential partnerships.

Key Dates

Keywords

reverse stock split, annual meeting, proxy statement, executive compensation, Nasdaq, directors, audit firm, corporate governance, stockholders, biopharmaceutical